TheraRadar
← Back
Data updated: Sep 20, 2026

AZURITY PHARMACEUTICALS INC

Pharma

AZURITY PHARMACEUTICALS INC is a pharmaceutical company focused on Neurology.

-
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

AZURITY PHARMACEUTICALS INC's Key Drugs

AZURITY PHARMACEUTICALS INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

AZURITY PHARMACEUTICALS INC's Recent FDA Approvals

New NDA/BLA approvals for AZURITY PHARMACEUTICALS INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AZURITY PHARMACEUTICALS INC's Therapeutic Areas

AZURITY PHARMACEUTICALS INC's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
0 drugs Phase 1: 1

AZURITY PHARMACEUTICALS INC's Top Competitors

AZURITY PHARMACEUTICALS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

AZURITY PHARMACEUTICALS INC Pipeline Snapshot

AZURITY PHARMACEUTICALS INC has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.

0
Phase 3
0
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling